During the past decade, Hospital São Paulo - UNIFESP conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 6 clinical trials were completed, i.e. on average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 3 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital São Paulo - UNIFESP" #1 sponsor was "Boehringer Ingelheim" with 3 trials, followed by "Hospital do Coracao" with 3 trials sponsored, "Eurofarma Laboratorios S.A." with 2 trials sponsored, "Federal University of São Paulo" with 2 trials sponsored and "Actelion" with 2 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital São Paulo - UNIFESP" #1 collaborator was "Brazilian Research In Intensive Care Network" with 2 trials as a collaborator, "Hospital Israelita Albert Einstein" with 2 trials as a collaborator, "Hospital Moinhos de Vento" with 2 trials as a collaborator, "Hospital Sirio-Libanes" with 2 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 2 trials as a collaborator. Other collaborators include 20 different institutions and companies that were collaborators in the rest 30 trials.

According to Clinical.Site data, the most researched conditions in "Hospital São Paulo - UNIFESP" are "Atrial Fibrillation" (2 trials), "Cardiovascular Diseases" (2 trials), "Coronary Artery Disease" (2 trials), "Heart Diseases" (2 trials) and "Acute Coronary Syndrome" (1 trials). Many other conditions were trialed in "Hospital São Paulo - UNIFESP" in a lesser frequency.

Most popular intervention types in "Hospital São Paulo - UNIFESP" are "Drug" (14 trials), "Device" (4 trials), "Procedure" (2 trials), "Behavioral" (1 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "1200 mg QD Eslicarbazepine acetate" (1 trials), "800 mg QD Eslicarbazepine acetate" (1 trials), "Antiplatelet Monotherapy" (1 trials) and "Antiplatelet treatment" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hospital São Paulo - UNIFESP" are 21 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Hospital São Paulo - UNIFESP". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Hospital São Paulo - UNIFESP, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital São Paulo - UNIFESP, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 2 trials that are defined as “Not Applicable".